You are here

cell therapy

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

Globe Newswire

Thu, 04/3/25 - 11:23 am

clinical trials

Biopharmas laid off staffers at least 63 times in Q1: Fierce Biotech analysis

Fierce Biotech

Tue, 04/1/25 - 11:46 am

ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains

Clinical Trials Arena

Tue, 04/1/25 - 11:34 am

heart failure with reduced ejection fraction

Vertex halts development of diabetes cell therapy after trial failure

Clinical Trials Arena

Mon, 03/31/25 - 10:51 am

Vertex Pharmaceuticals

type 1 diabetes

clinical trials

Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy

BioPharma Dive

Thu, 03/27/25 - 11:15 am

autoimmune disease

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

Morningstar

Wed, 03/26/25 - 10:19 pm

Despite raising $1B over past 5 years, ElevateBio lets go of 17% of workforce

Fierce Biotech

Wed, 03/26/25 - 10:16 pm

Adaptimmune, after bringing cell therapy to market, questions viability and cuts 2 preclinical

Fierce Biotech

Thu, 03/20/25 - 09:57 pm

Adaptimmune Therapeutics

BioNTech passes on Autolus’ CD19/CD22 CAR-T amid pipeline prioritization

Fierce Biotech

Thu, 03/20/25 - 11:13 am

Autolus Therapeutics

Cell therapy biotech Century Therapeutics axes cancer trial, turns to autoimmune

Fierce Biotech

Thu, 03/20/25 - 11:11 am

Century Therapeutics

autoimmune diseases

Cargo shelves cell therapy research and lays off almost all staff

BioPharma Dive

Wed, 03/19/25 - 11:18 am

Cargo Therapeutics

AstraZeneca makes potential $1B cell therapy play in EsoBiotec buy

BioSpace

Mon, 03/17/25 - 11:24 am

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

Fierce Pharma

Wed, 03/12/25 - 11:20 pm

Multiple Myeloma

2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M

BioPharma Dive

Tue, 03/11/25 - 11:33 am

Bristol Myers Squibb

Astellas shifts investment focus to later-stage opportunities amid reprioritization

Fierce Pharma

Wed, 02/12/25 - 09:23 pm

Vision loss biotech Aurion Biotech files for a $100 million IPO

Renaissance Capital

Mon, 01/27/25 - 11:29 am

5 questions facing emerging biotech in 2025

BioPharma Dive

Tue, 01/14/25 - 11:22 am

JPM25: Bayer moves allogeneic cell therapy into phase 3 Parkinson's trial

Fierce Biotech

Mon, 01/13/25 - 11:13 am

Parkinson's Disease

clinical trials

Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Fierce Biotech

Wed, 01/8/25 - 11:29 am

Sana Biotechnology

type 1 diabetes

Galapagos unveils plan to split, hiving off its drugs unit

Pharmaphorum

Wed, 01/8/25 - 11:13 am

Pages